Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm ...

(MENAFN- GlobeNewsWire - Nasdaq) Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE ...

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

India’s R&D needs faster, predictable approval timelines to boost investor confidence: Dr Jogin Desai: Our Bureau, Bengaluru Friday, April 17, 2026, 15:30 Hrs [IST] India’s re ...

Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...

Regulatory milestone supports broader adoption of C-mo's privacy-preserving technology in clinical research and medical practice Approval covers ...